[quick news] Friday, November 17, 2017

The list of "highly cited scientists" released in 2017 clarivate analytics recently released the list and white paper of "highly cited scientists" in 2017 In this year's list, more than 3000 scientific research elites from 900 institutions and 130000 highly cited papers in 21 fields of natural and social sciences have been selected The United States has the largest number of highly cited scientists, reaching 1644, a 12% increase from the 2016 list of highly cited scientists The UK is second with 344 researchers selected China ranked third, with 249 scientific researchers selected, achieving the highest growth of 41% There are 816 highly cited scientists in chemistry, clinical medicine, biology & Biotechnology Clarivate analytics https://clarivate.com/hcr/2017-researchers-list/ the first new hemophilia drug in 20 years was approved by the U.S FDA as a new drug hemlibra (emisizumab kxwh) for routine prevention, prevention or reduction of haemorrhagic events in adult and child patients with factor VIII inhibitors In two key clinical trials targeting such patients, hemlibra significantly reduced bleeding in adults and children Hemlibra is a bispecific factor IXa and factor X directed antibody It can restore the coagulation process of patients with hemophilia A A by aggregating factor IXa and factor X, the proteins needed to activate the natural coagulation cascade Hemlibra is a preventive treatment that can be administered by subcutaneous injection of solution once a week It is expected to provide new therapeutic options for hemophilia A patients who develop factor VIII inhibitors U S.food & drug https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm585567.htm recently, Sangamo therapeutics Co., Ltd completed the first patient administration of sb-913 This gene therapy is aimed at the rare genetic disease type II mucopolysaccharide storage syndrome (MPS II) Sb-913 inserts the correct gene into the specific site of hepatocyte genome by using the genome editing technology of zinc finger nuclease (ZFN) In order to limit the effect of this therapy to hepatocytes, AAV vector, which is responsible for delivering ZFN and correct genes, can target the liver After arriving at the liver, ZFN can be specifically activated in hepatocytes and recognize, bind and cut off specific sites in albumin gene Using the innate DNA repair mechanism of cells, hepatocytes can insert the gene encoding normal IDS into this site PR Newswire https://www.prnewswire.com/news-releases/sangamo-announcements-treatment-of-first-patient-in-landmark-phase-12-clinical-trial-evaluating-in-vivo-genome-editing-for-mps-ii-300556189.html intestinal bacteria inhibit host natural immune defense scientists found the intestinal pathogen Shigella Flexneri), the molecular mechanism of its anti host immune defense They showed that the effector protein, ipah9.8, secreted by Shigella Shigella during mouse infection, inhibits host immune response by ubiquitination and degradation of guanylate binding protein in host cells The loss or destruction of the activity of ipah9.8 can make GBP inhibit the growth of bacteria Ipah9.8 target host GBP represents a new mechanism of pathogenic bacteria inhibiting host innate immune defense Nature https://www.nature.com/articles/nature24467 for the first time in 14 years, American Heart redefines the standard of hypertension Association, AHA) recently released "2017 adult hypertension guidelines", which revised the 2003 version of hypertension detection and treatment program, which has been used for more than 14 years, and reduced the definition standard of hypertension from 140 / 90 (systolic / diastolic) mm Hg to 130 / 80 mm Hg Reducing the definition value of hypertension reflects the importance of early intervention When the blood pressure reaches 130 / 80 mmHg, intervention can prevent more complications of hypertension American Heart Association https://newsroom.heart.org/news/high-blood-pressure-redefined-for-first-time-in-14-years-130-is-the-new-high